FIELD: medicine; pharmaceuticals.
SUBSTANCE: use of a polymeric prodrug is proposed that is a D-L conjugate for intra-articular injection to treat joint diseases, where D is a biologically active fragment containing a primary or secondary amine, and L is a biologically inactive linker fragment L1 of Formula (VII), with L1 substituted by one group L2-Z where L2 is a single chemical bond or spacer and where Z is a water-insoluble hydrogel based on polyethylene glycol (PEG) and hyaluronic acid. There are also proposed a pharmaceutical composition comprising said polymeric prodrug together with one or more pharmaceutically acceptable excipients, and a method of treating a disease of the joints by administering a therapeutically effective amount of said polymeric prodrug or said pharmaceutical composition.
EFFECT: group of inventions provides therapy of joint diseases by intra-articular injection.
9 cl, 22 ex, 1 dwg
Title | Year | Author | Number |
---|---|---|---|
HYDROCARBON GEL-BASED PRODRUGS | 2013 |
|
RU2647729C2 |
VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | 2013 |
|
RU2673881C2 |
BIODEGRADABLE WATER-INSOLUBLE POLYETHYLENEGLYCOL-BASED HYDROGELS | 2010 |
|
RU2554854C9 |
PRODRUG CONTAINING A SELF-CLEAVABLE LINKER | 2018 |
|
RU2798085C2 |
PRODRUGS CONTAINING INSULIN LINKER CONJUGATE | 2010 |
|
RU2574667C2 |
PRODRUG CONTAINING SELF-CLEAVABLE LINKER | 2014 |
|
RU2676324C2 |
PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATMENT OF GROWTH HORMONE-RELATED DISEASES IN HUMANS | 2019 |
|
RU2802215C2 |
CNP PRODRUGS | 2016 |
|
RU2824988C1 |
RTN PRODRUGS | 2017 |
|
RU2747316C2 |
Authors
Dates
2019-03-20—Published
2013-10-08—Filed